
...

By Hollie Silverman
News Editor
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
President Donald Trump signed an executive order Saturday directing federal agencies to speed reviews of certain psychedelic drugs, including ibogaine, as veterans and some conservative lawmakers pushed for expanded research despite known safety risks.
Trump said the directive would “dramatically accelerate” access to research and potential treatments and noted certain psychedelics had already been designated as possible breakthroughs by regulators.
"In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans," Trump said during a signing in the Oval Office on Saturday. "Our veterans are having a tremendous hard time."
Read More on News
Following the signing, former Navy SEAL Marcus Luttrell told Trump, “You’re going to save a lot of lives through it. It absolutely changed my life for the better.”
Why It Matters
The order marked the first time the Food and Drug Administration (FDA) moved to offer priority vouchers for psychedelics, a step that could expedite reviews if proposals align with national priorities.
Veterans continue to face severe mental health challenges, with data from a 2025 study published by the National Library of Medicine showing more than one in five experiences post-traumatic stress (PTSD) each year—a rate nearly five times higher than among civilians.
Advocates say depression, anxiety, substance use disorders, and elevated suicide risk remain widespread among veterans, often linked to combat exposure, military sexual trauma, and the difficult transition back to civilian life.
What To Know
Trump signed the executive order Saturday morning at a ceremony attended by lawmakers, veterans and podcaster Joe Rogan, who said he had contacted the president about the treatment.
Ibogaine was among the drugs included in Trump's research order. While it remains a Schedule I controlled substance, reports that some veterans traveling abroad for treatment saw improvements in PTSD and depression have received renewed attention amid the order.
Rogan said he heard about these treatments during a taping of his podcast and sent Trump “some information” about them.
“I sent him that information. The text message that came back: ‘Sounds great. Do you want FDA approval? Let’s do it.’ Literally that quick,” Rogan said.
No psychedelics were legalized by the executive order, but ibogaine and other psychedelics such as psilocybin, MDMA and LSD remain Schedule I substances under federal law, according to the Associated Press.
The order directed agencies to speed reviews and facilitate research pathways, including issuing FDA national priority review vouchers for three psychedelics and clearing a path toward the first U.S. human trials of ibogaine.
Texas approved $50 million to fund ibogaine trials last year with support from veterans groups and former Texas Governor Rick Perry, potentially accelerating clinical research that might lead to FDA reviews.

...
What Is Ibogaine?
Ibogaine is a psychoactive alkaloid derived from the root bark of the African shrub Tabernanthe iboga and has been used in Bwiti religious ceremonies in Central and West Africa, according to a study published in July 2025 by Nature Mental Health, cited by Stanford Medicine.
In recent years, U.S. veterans have sought ibogaine treatment in clinics outside the country, including Mexico, reporting improvements in PTSD, depression and anxiety, findings echoed in small Stanford-associated studies of special operations veterans who received ibogaine with magnesium under medical monitoring in Mexico, according to Stanford Medicine in 2024.
Safety concerns remain significant as ibogaine has been associated with abnormal heart rhythms and more than 30 deaths, according to the Multidisciplinary Association for Psychedelic Studies.
“It’s been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity,” Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, told the AP. “If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others."
How Does Ibogaine Work?
Researchers have proposed that ibogaine modulates multiple neurotransmitter systems and may promote neuroplasticity.
Data from Stanford Medicine shows a link in symptom improvements to changes in brain activity patterns such as increased theta rhythms and reduced cortical complexity among treated veterans.
In one Stanford-associated cohort study of 30 veterans treated in Mexico, participants reported large reductions in PTSD, depression and anxiety at one month, though the study did not include a placebo control and therefore cannot establish causality, according to Stanford Medicine.
What Happens Next
Clinic operators said near-term access would remain largely unchanged because ibogaine is still unapproved and not covered by insurance, though the order could reduce stigma and encourage state research funding.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines